We provide you with 20 years of free, institutional-grade data for ATOS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ATOS. Explore the full financial landscape of ATOS stock.
| Reported Date | CIK | Ticker | Type |
|---|
Atossa Therapeutics, Inc(NASDAQ:ATOS) 
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cance...
Website: http://www.atossagenetics.com
Founded: 2008
Full Time Employees: 4
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about ATOS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.